PF-Atlas › Clinical Trials › NCT04419558

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis

Pamrevlumab · Phase 3

Registry ID
NCT04419558
Phase
Phase 3
Status
Terminated
Drug / intervention
Pamrevlumab
Sponsor
Kyntra Bio
Start
2020-09-30
Enrollment
372
Locations
157

About this trial

This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). There is a 48-week randomized treatment phase followed by an optional, open-label extension phase.

View NCT04419558 on ClinicalTrials.gov →

Explore related

All Pamrevlumab trialsAll IPF trials

Related trials

Pamrevlumab — ZEPHYRUS-2Pamrevlumab — NCT03955146Pamrevlumab — NCT01890265
Medical disclaimer. This page summarizes public trial data for NCT04419558 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.